5-Propanoylspiro[1-benzofuran-2,1'-cyclopropane]-3-one | 77527-08-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-Propanoylspiro[1-benzofuran-2,1'-cyclopropane]-3-one
• CAS: 77527-08-3
• 化学式: C₁₃H₁₂O₃
• 分子量: 216.236
• InChiKey: WXYOPJJSFFJAPB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-hydroxy-5-propionyl-benzoic acid methyl ester 在 potassium carbonate 、 三乙胺 、 sodium chloride 作用下， 以 乙酸酐 、 二甲基亚砜 、 丙酮 为溶剂， 反应 47.5h， 生成 5-Propanoylspiro[1-benzofuran-2,1'-cyclopropane]-3-one
  参考文献：
  名称：

  Spirocyclopropane compounds. III. Synthesis of spiro(benzofuran-2(3H),1'-cyclopropan)-3-ones for evaluation as gastric antisecretory and antiulcer agents.

  摘要：

  苯并呋喃-2(3H),1'-环丙烷]-3-酮（VI-1）及其衍生物（VI-2至VI-75）按照之前合成螺[环丙烷-1,2'-[2H]吲哚]-3'(1'H)-酮（I）的方法合成了。这些螺[苯并呋喃-2(3H),1'-环丙烷]-3-酮被评估了其抗胃液分泌活性和对大鼠水浸束缚应激诱导的损伤的保护活性。通过在苯环的5位引入乙酰基或二甲氨基，获得了最具效力的抗溃疡化合物（VI-17和VI-55）。该系列中最有趣的成员，5-乙酰基螺[苯并呋喃-2(3H),1'-环丙烷]-3-酮（VI-17，AG-629），被选为临床研究的候选药物。

  DOI：

  10.1248/cpb.32.3532

文献信息

• Triazole Derivative and Use Thereof
  申请人：Kubo Keiji

  公开号：US20090105253A1

  公开（公告）日：2009-04-23

  The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R 1a , R 1b and R 2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R 3 is a group represented by the formula —NHCOR 4 , —NHSO 2 R 5 , —NHCON(R 6a )(R 6b ), —NHCOOR 7 or —CONHR 8 wherein R 4 , R 5 , R 6a , R 6b , R 7 and R 8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R 1a and R 1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

  本发明涉及一种含有式(I)所表示的化合物的凝血酶受体拮抗剂，其中R1a、R1b和R2分别是氢原子、可选取代的碳氢基团、可选取代的杂环基团或可选取代的烷氧基，R3是由式—NHCOR4、—NHSO2R5、—NHCON(R6a)(R6b)、—NHCOOR7或—CONHR8所表示的基团，其中R4、R5、R6a、R6b、R7和R8分别是氢原子、可选取代的碳氢基团、可选取代的杂环基团等，环A是单环芳香环，可选地进一步具有取代基，R1a和R1b可选择性地连接在一起形成可选取代的含氮非芳香杂环，或其盐或前药。本发明的凝血酶受体拮抗剂具有凝血酶受体（特别是PAR-1）拮抗作用，可用于预防或治疗PAR-1介导的病理状态或疾病。
• TRIAZOLE DERIVATIVE AND THE USE THEREOF
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1867331A1

  公开（公告）日：2007-12-19

  The present invention relates to a thrombin receptor antagonist containing a compound represented by the formula (I) wherein R1a, R1b and R2 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or an optionally substituted alkoxy, R3 is a group represented by the formula -NHCOR4, -NHSO2R5, -NHCON(R6a) (R6b), -NHCOOR7 or -CONHR8 wherein R4, R5, R6a, R6b, R7 and R8 are each a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group and the like), ring A is monocyclic aromatic ring optionally further having substituent(s), R1a and R1b are optionally bonded to each other to form an optionally substituted nitrogen-containing non-aromatic heterocycle, or a salt thereof or a prodrug thereof. The thrombin receptor antagonist of the present invention has a thrombin receptor (particularly PAR-1) antagonistic action and is useful for the prophylaxis or treatment of PAR-1 mediated pathological condition or disease.

  本发明涉及一种凝血酶受体拮抗剂，其中含有由式（I）代表的化合物 其中 R1a、R1b 和 R2 各为氢原子、任选取代的烃基、任选取代的杂环基团或任选取代的烷氧基，R3 为由式 -NHCOR4、-NHSO2R5、-NHCON(R6a) (R6b)、-NHCOOR7 或 -CONHR8 所代表的基团，其中 R4、R5、R6a、R6b、R7 和 R8 各为氢原子、任选取代的烃基、任选取代的杂环基等），环 A 是单环芳香环，任选进一步具有取代基，R1a 和 R1b 任选相互键合以形成任选取代的含氮非芳香杂环，或其盐或其原药。本发明的凝血酶受体拮抗剂具有凝血酶受体（尤其是 PAR-1）拮抗作用，可用于预防或治疗 PAR-1 介导的病理状态或疾病。
• KAWADA, MITSURU;WATANABE, MASAZUMI;OKAMOTO, KAYOKO;SUGIHARA, HIROSADA;HRA+, CHEM. AND PHARM. BULL., 1984, 32, N 9, 3532-3550
  作者：KAWADA, MITSURU、WATANABE, MASAZUMI、OKAMOTO, KAYOKO、SUGIHARA, HIROSADA、HRA+

  DOI：——

  日期：——
• US7803822B2
  申请人：——

  公开号：US7803822B2

  公开（公告）日：2010-09-28
• Spirocyclopropane compounds. III. Synthesis of spiro(benzofuran-2(3H),1'-cyclopropan)-3-ones for evaluation as gastric antisecretory and antiulcer agents.
  作者：MITSURU KAWADA、MASAZUMI WATANABE、KAYOKO OKAMOTO、HIROSADA SUGIHARA、TAKEO HIRATA、YOSHITAKA MAKI、ISUKE IMADA、YASUSHI SANNO

  DOI：10.1248/cpb.32.3532

  日期：——

  Spiro [benzofuran-2 (3H), 1'-cyclopropan]-3-one (VI-1) and its derivatives (VI-2-VI-75) were synthesized in the same manner as described previously for the synthesis of spiro [cyclopropane-1, 2'-[2H] indol]-3'(1'H)-ones (I). These spiro [benzofuran-2 (3H), 1'-cyclopropan]-3-ones were evaluated for gastric antisecretory activity and protective activity against lesions induced by water-immersion restraint stress in the rat. The most potent antiulcer compounds (VI-17 and VI-55) were obtained by the introduction of an acetyl or dimethylamino group at the 5-position on the benzene ring. The most interesting member of the series, 5-acetylspiro [benzofuran-2 (3H), 1'-cyclopropan]-3-one (VI-17, AG-629), was selected as a candidate for clinical studies.

  苯并呋喃-2(3H),1'-环丙烷]-3-酮（VI-1）及其衍生物（VI-2至VI-75）按照之前合成螺[环丙烷-1,2'-[2H]吲哚]-3'(1'H)-酮（I）的方法合成了。这些螺[苯并呋喃-2(3H),1'-环丙烷]-3-酮被评估了其抗胃液分泌活性和对大鼠水浸束缚应激诱导的损伤的保护活性。通过在苯环的5位引入乙酰基或二甲氨基，获得了最具效力的抗溃疡化合物（VI-17和VI-55）。该系列中最有趣的成员，5-乙酰基螺[苯并呋喃-2(3H),1'-环丙烷]-3-酮（VI-17，AG-629），被选为临床研究的候选药物。